Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis

PURPOSE: Ductal carcinoma in situ (DCIS) is present in more than half of HER2-positive invasive breast cancer (IBC). Recent studies show that DCIS accompanying HER2-positive IBC can be completely eradicated by neoadjuvant systemic therapy (NST). Our aim was to determine the percentage of pathologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ploumen, Roxanne A. W., Claassens, Eva L., Kooreman, Loes F. S., Keymeulen, Kristien B. M. I., van Kats, Maartje A. C. E., Gommers, Suzanne, Siesling, Sabine, van Nijnatten, Thiemo J. A., Smidt, Marjolein L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361905/
https://www.ncbi.nlm.nih.gov/pubmed/37395816
http://dx.doi.org/10.1007/s10549-023-07012-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361905/
https://www.ncbi.nlm.nih.gov/pubmed/37395816
http://dx.doi.org/10.1007/s10549-023-07012-z

Ejemplares similares